Literature DB >> 12584561

Decreased syndecan-2 expression correlates with trichostatin-A induced-morphological changes and reduced tumorigenic activity in colon carcinoma cells.

Yeonhee Kim1, Haein Park, Yangmi Lim, Innoc Han, Ho Jeong Kwon, Anne Woods, Eok-Soo Oh.   

Abstract

The inhibition of histone deacetylase activity is known to induce morphological changes of transformed cells. In this study, we investigated the effect of the specific HDAC inhibitor, trichostatin A (TSA), on colon carcinoma cell lines. Treatment of human colorectal carcinoma cells, KM1214 and KM12SM, with TSA induced distinct morphological changes. Both cell lines, which normally piled up in layers without clear boundary, became more flattened, and formed monolayers with evident boundaries between cells, with concomitant increased actin filament organization. Cell-cell interaction was not affected much, based on expression level, membrane localization, and interaction of E-cadherin with beta-catenin. In contrast, syndecan-2 expression was dramatically reduced and it was correlated with the morphological changes of colon carcinoma cells. Consistently, downregulation of syndecan-2 expression by antisense cDNA clearly mimicked the morphological changes in KM12SM and reduced anchorage-independent growth of colon cancer cells. All these results indicate that reduced syndecan-2 expression correlates with TSA-induced morphological changes and reduced tumorigenic activity in colon carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12584561     DOI: 10.1038/sj.onc.1206068

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

Review 1.  New insights into syndecan-2 expression and tumourigenic activity in colon carcinoma cells.

Authors:  Innoc Han; Haein Park; Eok-Soo Oh
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

2.  Syndecan-2 regulates the migratory potential of melanoma cells.

Authors:  Jung-hyun Lee; Haein Park; Heesung Chung; Sojoong Choi; Younghwa Kim; Hyun Yoo; Tae-Yoon Kim; Hoo-Jae Hann; Ikjoo Seong; Jaesang Kim; Kathleen G Kang; Inn-Oc Han; Eok-Soo Oh
Journal:  J Biol Chem       Date:  2009-07-29       Impact factor: 5.157

3.  Syndecan-2 functions as a docking receptor for pro-matrix metalloproteinase-7 in human colon cancer cells.

Authors:  Heui-Young Ryu; Jiseon Lee; Sanghwa Yang; Haein Park; Sojoong Choi; Kyeong-Cheon Jung; Seung-Taek Lee; Je-Kyung Seong; Inn-Oc Han; Eok-Soo Oh
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

4.  Syndecan-2 promotes perineural invasion and cooperates with K-ras to induce an invasive pancreatic cancer cell phenotype.

Authors:  Tiago De Oliveira; Ivane Abiatari; Susanne Raulefs; Danguole Sauliunaite; Mert Erkan; Bo Kong; Helmut Friess; Christoph W Michalski; Jörg Kleeff
Journal:  Mol Cancer       Date:  2012-04-03       Impact factor: 27.401

Review 5.  Syndecans in tumor cell adhesion and signaling.

Authors:  DeannaLee M Beauvais; Alan C Rapraeger
Journal:  Reprod Biol Endocrinol       Date:  2004-01-07       Impact factor: 5.211

6.  Histone Deacetylase Inhibitor Trichostatin a Promotes the Apoptosis of Osteosarcoma Cells through p53 Signaling Pathway Activation.

Authors:  Zhantao Deng; Xiaozhou Liu; Jiewen Jin; Haidong Xu; Qian Gao; Yong Wang; Jianning Zhao
Journal:  Int J Biol Sci       Date:  2016-10-18       Impact factor: 6.580

7.  Tyrosine 51 residue of the syndecan-2 extracellular domain is involved in the interaction with and activation of pro-matrix metalloproteinase-7.

Authors:  Bohee Jang; Ji-Hye Yun; Sojoong Choi; Jimin Park; Dong Hae Shin; Seung-Taek Lee; Weontae Lee; Eok-Soo Oh
Journal:  Sci Rep       Date:  2019-07-23       Impact factor: 4.379

8.  The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells.

Authors:  DeannaLee M Beauvais; Brandon J Burbach; Alan C Rapraeger
Journal:  J Cell Biol       Date:  2004-10-11       Impact factor: 10.539

9.  PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma.

Authors:  Guanzhen Yu; Wenlong Yu; Guangzhi Jin; Dongyun Xu; Ying Chen; Tian Xia; Allan Yu; Wenzheng Fang; Xiaoli Zhang; Zhaosheng Li; Keping Xie
Journal:  Mol Cancer       Date:  2015-11-14       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.